## ICMJE DISCLOSURE FORM

Date:	_8/5/2021		
Your Name:	Rimas V Lukas		
Manuscript Title: An International Perspective on the Management of Glioblastoma			
Manuscript nu	umber (if known):CCO-2019-EMG-09 (CCO-21-107)		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	NIH P50CA221747 BrainUp 2136
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

Г	Doumont or hereite for	Nonc	Novosuro Spockors' hurson
5	Payment or honoraria for	None	Novocure-Speakers' bureau
	lectures, presentations,		American Physician Institute-CME content creation and
	speakers bureaus,		presentation
	manuscript writing or		EBSCO Publishing-medical editing
	educational events		
			Medlink Neurology-medical editing
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
-	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
1			
9	Participation on a Data	None	Novocure-Scientific Advisory Board
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
10	in other board, society,		
1	-		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	None	BMS-Research support (drug only)
	materials, drugs, medical		
1	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

## Please summarize the above conflict of interest in the following box:

Dr RV Lukas has received research support from NIH P50CA221747, BrainUp 2136, and BMS (drug only). Dr RV Lukas has received honoraria from serving on a scientific advisory board and speakers' bureau for Novocure. Dr RV Lukas has received honoraria for medical editing for EBSCO Publishing and Medlink Neurology and for the creation and presentation of CME board review content for American Physician Institute.

#### Please place an "X" next to the following statement to indicate your agreement:

# \_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

Date: Friday, August 6, 2021				
Your Name: Evangelia Razi				
Manuscript Title: An International Perspective on the Management of Glioblastoma				
Manuscript number (if known): CCO-2019-EMG-09(CCO-21 107)				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the finitia	
1	All support for the present manuscript (e.g., funding,	Novartis	Research Funding
	provision of study materials,	Parexel	Research Funding
	medical writing, article processing charges, etc.)	Tesaro	Research Funding
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_X_None	
	in item #1 above).		
3	Royalties or licenses	_X_None	
4	Consulting fees	AstraZeneca	Consulting
		Bristol Mayer Squibb	Consulting

5 Payment or honoraria for	Bristol Mayer Squibb	Honoraria	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
_			
7	Support for attending	Leo Pharma, Roche,	Travel, Accommodations Expenses
	meetings and/or travel	Genekor, Merck, Ipsen	
		Sanofi, Novartis, Pfizer,	Travel, Accommodations Expenses
		Bristol Mayer Squibb	Turnel Arrange defines Free array
		Genesis Pharmaceuticals	Travel, Accommodations Expenses
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	AstraZeneca	Advisory Role
	Safety Monitoring Board or	Bristol Mayer Squibb	Advisory Role
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Dessint of equipment	V. Nono	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

# Please summarize the above conflict of interest in the following box:

Research Funding-Novartis, Paraxel, Tesaro. Consulting or Advisory Role – AstraZeneca, Bristol Mayer Squibb. Bristol Mayer Squibb- Honoraria. Travel, accommodations expenses- Leo Pharma, Roche, Genekor, Merck, Ipsen, Sanofi, Novartis, Pfizer, Bristol Mayer Squibb, Genesis Pharmaceuticals.

## Please place an "X" next to the following statement to indicate your agreement:

# \_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:	8/5/2021
Your Name:	_Jason T Huse
Manuscript Title:_	_An International Perspective on the Management of Glioblastoma
Manuscript numbe	er (if known):CCO-2019-EMG-09(CCO-21-107)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

# Please summarize the above conflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.